8-K filing — Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Filed: 2026-10-15 AccNo: 0001193125-26-422437 Size: 26 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Corbus Pharmaceuticals reports positive Phase 1b trial results for obesity drug CRB-913, demonstrating significant 12-week weight loss.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Corbus Pharmaceuticals Announces First Patient Dosed In Registrational TEMPO-1 Study Of CRB-701 In Oropharyngeal Cancer
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.